Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Analyst Recommendations
This is a summary of current ratings and price targets for Atara Biotherapeutics and Taysha Gene Therapies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atara Biotherapeutics | 1 | 1 | 1 | 1 | 2.50 |
| Taysha Gene Therapies | 1 | 0 | 12 | 2 | 3.00 |
Atara Biotherapeutics presently has a consensus target price of $9.50, indicating a potential upside of 15.43%. Taysha Gene Therapies has a consensus target price of $12.77, indicating a potential upside of 198.35%. Given Taysha Gene Therapies’ stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Atara Biotherapeutics.
Risk & Volatility
Profitability
This table compares Atara Biotherapeutics and Taysha Gene Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atara Biotherapeutics | -269.42% | N/A | -73.01% |
| Taysha Gene Therapies | N/A | -56.19% | -41.84% |
Valuation and Earnings
This table compares Atara Biotherapeutics and Taysha Gene Therapies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atara Biotherapeutics | $120.77 million | 0.68 | $32.69 million | ($1.18) | -6.97 |
| Taysha Gene Therapies | $9.77 million | 142.74 | -$109.00 million | ($0.42) | -10.19 |
Atara Biotherapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Taysha Gene Therapies beats Atara Biotherapeutics on 10 of the 15 factors compared between the two stocks.
About Atara Biotherapeutics
Atara Biotherapeutics is a biopharmaceutical company focused on developing allogeneic T-cell immunotherapies for cancer and serious diseases associated with Epstein-Barr virus (EBV). The company’s platform uses donor-derived, virus-specific T cells that are designed to recognize and eliminate infected or malignant cells without requiring cells to be collected from each individual patient. Atara’s lead product, tabelecleucel, is marketed in the European Union under the brand name Ebvallo. The therapy is approved for certain adults and children with EBV-positive post-transplant lymphoproliferative disease, a rare and potentially life-threatening complication that can occur after organ or stem-cell transplantation.
About Taysha Gene Therapies
Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company’s lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha’s research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
